Elixirgen Therapeutics
Latest round
- Series A
Last raised
- Jun 2018
Total raised
- $4M
Investors
- 1
About Elixirgen Therapeutics
Elixirgen Therapeutics is focused on biotechnology for the treatment of rare diseases and aging-related conditions. The company was founded in 2017 in Baltimore, US by Minoru Ko, with Akihiro Ko serving as CEO.Elixirgen Therapeutics specializes in advanced biotechnological products aimed at treating rare diseases and aging-associated conditions. The company's primary offerings include ZSCAN4 and Bobcat® mRNA technologies, which are designed to address significant unmet medical needs. ZSCAN4 focuses on extending telomeres through a telomerase-independent mechanism, targeting conditions such as Telomere Biology Disorders, myelodysplastic syndromes (MDS), and idiopathic pulmonary fibrosis (IPF). Bobcat® mRNA serves as a gene therapy vector capable of delivering large genetic payloads, including the full-length dystrophin protein for patients with Duchenne muscular dystrophy (DMD). These innovations are currently under clinical evaluation, with ZSCAN4 undergoing Phase I/II trials at Cincinnati Children’s Hospital Medical Center.Elixirgen Therapeutics generates revenue through partnerships and clinical collaborations rather than direct consumer sales. The company is involved in strategic partnerships with healthcare institutions and biopharmaceutical companies to further develop and commercialize its therapeutic candidates, which include proprietary products such as EXG-34217 for Telomere Biology Disorders and EXG-7001 targeting DMD. These partnerships aid in covering development costs while simultaneously facilitating the pathway to eventual commercialization of their therapies. The company is focusing on expanding its clinical trials and aims to launch new products targeting rare genetic disorders within the next few years. Geographic expansion into international markets, particularly in Europe and Asia, is also a critical goal, with a target timeline set for the next two to three years to enhance their market presence.
Who invested in Elixirgen Therapeutics
1 investor across 1 round
See all investors in Elixirgen Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 22, 2018
Amount
$4M
Investors
Questions about Elixirgen Therapeutics
Who invested in Elixirgen Therapeutics?
Elixirgen Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Elixirgen Therapeutics raised?
Elixirgen Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Elixirgen Therapeutics last raise money?
Elixirgen Therapeutics's most recent round on record is a Series A, in Jun 2018.
What does Elixirgen Therapeutics do?
Elixirgen Therapeutics is focused on biotechnology for the treatment of rare diseases and aging-related conditions.
Where is Elixirgen Therapeutics headquartered?
Elixirgen Therapeutics is headquartered in Baltimore, US.
Which VCs invest in companies like Elixirgen Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Elixirgen Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Elixirgen Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.